GLP-1 Pathway drugs (Incretin Therapy) for Diabetes Melitus: Physiology, Clinical Rationale and Implications for the Exocrine Pancreas

被引：0
|
作者：
Fine, David
机构：
来源：
PANCREATOLOGY | 2016年 / 16卷 / 01期
关键词：
D O I：
10.1016/j.pan.2016.01.008
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1 / 1
页数：1
相关论文
共 30 条
  • [1] GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
    Holst, Jens Juul
    NATURE METABOLISM, 2024, 6 (10) : 1866 - 1885
  • [2] From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
    Holst, Jens Juul
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [3] GLP-1 and type 2 diabetes: physiology and new clinical advances
    Combettes, Murielle M. J.
    CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (06) : 598 - 605
  • [4] GLP-1-Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy
    Holst, Jens Juul
    Jepsen, Sara Lind
    Modvig, Ida
    CURRENT OPINION IN PHARMACOLOGY, 2022, 63
  • [5] The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists
    van Baar, Michael J. B.
    van der Aart, Annemarie B.
    Hoogenberg, Klaas
    Joles, Jaap A.
    Heerspink, Hiddo J. L.
    van Raalte, Daniel H.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2019, 10
  • [6] Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management
    Delrue, Charlotte
    Speeckaert, Marijn M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (17)
  • [7] Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications
    Zhang, Xinyu
    Cao, Chao
    Zheng, Fei
    Liu, Chang
    Tian, Xiuqing
    CARDIOVASCULAR DRUGS AND THERAPY, 2025,
  • [8] GLP-1 Analogs for Therapy of Multiple Sclerosis (MSGLP): Design, Methods and Rationale of Randomized, Controlled Clinical Trial
    Imrich, Richard
    Penesova, Adela
    Vlcek, Miroslav
    Radikova, Zofia
    Havranova, Andrea
    Siarnik, Pavol
    Sivakova, Monika
    Kollar, Branislav
    Turcani, Peter
    NEUROTHERAPEUTICS, 2020, 17 (03) : 1316 - 1316
  • [9] Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
    Mann, Johannes F. E.
    Muskiet, Marcel H. A.
    KIDNEY INTERNATIONAL, 2021, 99 (02) : 314 - 318
  • [10] GLP-1 receptor agonists affect beta cell activation, activity, and deactivation in acute mouse pancreas tissue slices: Implications for incretin-mediated amplification
    Leitgeb, Eva Paradiz
    Kercmar, Jasmina
    Bombek, Lidija Krizancic
    Pohorec, Viljem
    Rupnik, Marjan Slak
    Klemen, Masa Skelin
    Gosak, Marko
    Dolensek, Jurij
    Stozer, Andraz
    ACTA PHYSIOLOGICA, 2023, 239
123